Literature DB >> 11369036

SKF83959 exhibits biochemical agonism by stimulating [(35)S]GTP gamma S binding and phosphoinositide hydrolysis in rat and monkey brain.

S Panchalingam1, A S Undie.   

Abstract

SKF83959, a benzazepine with high affinity for aminergic receptors, elicits behaviors such as grooming and vacuous chewing that are characteristic of dopamine D(1)-like receptor stimulation in rodents. Unlike classical D(1) agonists, however, SKF83959 does not stimulate adenylyl cyclase. Knowing that some D(1)-like receptors are coupled to phospholipase C-mediated signaling cascades in the brain, the present study aimed to determine whether SKF83959 exhibits an agonistic action at the biochemical level and also whether this benzazepine can modulate phosphoinositide hydrolysis in a manner that would be consistent with the behavioral effects of the drug. Similar to dopamine and the selective D(1)-like agonist SKF38393, SKF83959 competitively displaced the receptor binding of [(3)H]dopamine in an agonist-like manner, significantly stimulated [(35)S]guanosine-5'-O-(3-thio)triphosphate binding, and potently enhanced phospholipase C-mediated phosphoinositide hydrolysis in rat and monkey brain tissues. SKF83959 was generally more potent than SKF38393, whereas SKF38393 consistently exhibited greater pharmacological efficacy. These findings may implicate a role for the phospholipase C signaling cascade in the agonistic behavioral and antiparkinsonian activity of SKF83959. Dopamine-sensitive phospholipase C signaling should probably be considered in subsequent formulations of mechanisms and models of dopaminergic function in the normal or diseased brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369036     DOI: 10.1016/s0028-3908(01)00011-9

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  30 in total

Review 1.  Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Authors:  Ashiwel S Undieh
Journal:  Pharmacol Ther       Date:  2010-06-12       Impact factor: 12.310

Review 2.  Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface.

Authors:  John L Waddington; Colm O'Tuathaigh; Gerard O'Sullivan; Katsunori Tomiyama; Noriaki Koshikawa; David T Croke
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

3.  Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822.

Authors:  David Wirtshafter
Journal:  Pharmacol Biochem Behav       Date:  2007-01-20       Impact factor: 3.533

4.  Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.

Authors:  Jennie L Conroy; R Benjamin Free; David R Sibley
Journal:  ACS Chem Neurosci       Date:  2015-02-20       Impact factor: 4.418

5.  Effects of SKF83959 on the excitability of hippocampal CA1 pyramidal neurons: a modeling study.

Authors:  Shang-Lin Zhou; Hong-Yuan Chu; Guo-Zhang Jin; Jian-Min Cui; Xue-Chu Zhen
Journal:  Acta Pharmacol Sin       Date:  2014-05-26       Impact factor: 6.150

6.  SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C.

Authors:  Sang-Min Lee; Andrew Kant; Daniel Blake; Vishakantha Murthy; Kevin Boyd; Steven J Wyrick; Richard B Mailman
Journal:  Neuropharmacology       Date:  2014-06-12       Impact factor: 5.250

7.  Electrophysiological effects of SKF83959 on hippocampal CA1 pyramidal neurons: potential mechanisms for the drug's neuroprotective effects.

Authors:  Hong-Yuan Chu; Qinhua Gu; Guo-Zhang Jin; Guo-Yuan Hu; Xuechu Zhen
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

8.  D5 dopamine receptors are required for dopaminergic activation of phospholipase C.

Authors:  Asha Sahu; Kimberly R Tyeryar; Habiba O Vongtau; David R Sibley; Ashiwel S Undieh
Journal:  Mol Pharmacol       Date:  2008-12-01       Impact factor: 4.436

9.  D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms.

Authors:  Lani S Chun; R Benjamin Free; Trevor B Doyle; Xi-Ping Huang; Michele L Rankin; David R Sibley
Journal:  Mol Pharmacol       Date:  2013-05-16       Impact factor: 4.436

Review 10.  Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?

Authors:  Sang-Min Lee; Yang Yang; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2014-07-22       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.